Kymera Therapeutics Inc美股招股说明书(2025-12-08版)

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. Aregistration statement has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplementand the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in anyjurisdiction where the offer or sale is not permitted. PRELIMINARY PROSPECTUS SUPPLEMENT(To Prospectus dated October31, 2024) $500,000,000 Shares of Common Stock We are offeringof shares of common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “KYMR.” On December 5,2025, the last reported sale price of our common stock on The Nasdaq Global Market was $66.62 per share. Investing in our securities involves significant risks that are described in the “Risk Factors” section beginning on pageS-12 ofthis prospectus supplement and page2 of the accompanying prospectus, and in the other documents that are incorporated byreference herein. You should read the entire prospectus supplement and the accompanying prospectus, including anyinformation incorporated by reference herein or therein, carefully before you make your investment decision. (1)See the section titled “Underwriting” beginning on pageS-20 of this prospectus supplement for a description of the compensation payable to theunderwriters. We have granted the underwriters an option for a period of 30 days to purchase an additional $75,000,000 of shares of our common stock from us, at the publicoffering price, less the underwriting discounts and commissions. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if thisprospectus supplement and the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock against payment therefor on or about, 2025. Joint book-running managers JefferiesWells Fargo Securities , 2025. Table of Contents TABLE OF CONTENTS PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENTAbout This Prospectus SupplementCautionary Statement Regarding Forward-Looking StatementsProspectus Supplement SummaryThe OfferingRisk FactorsDividend PolicyUse of ProceedsDilutionUnderwritingMaterial U.S. Federal Income Tax Considerations for Investors in Common StockLegal MattersExpertsWhere You Can Find More InformationIncorporation by Reference PROSPECTUSAbout This ProspectusRisk FactorsCautionary Note Regarding Forward-Looking StatementsThe CompanyUse of ProceedsSecurities We and/or Selling Stockholders May Offer or SellDescription of Capital StockDescription of Debt Securities Description of Warrants Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document is part of the automatic shelf registration statement on Form S-3 (File No.333-282912) that we filed with the Securities andExchange Commission, or the SEC, as a “well-known seasoned issuer” as defined in Rule 405 under the Securities Act of 1933, as amended, or theSecurities Act, using a “shelf” registration process, and consists of two parts. The first part is this prospectus supplement, including the documentsincorporated by reference herein, which describes the specific terms of this offering of common stock. The second part, the accompanying prospectus,including the documents incorporated by reference therein, gives more general information, some of which may not apply to this offering. Generally,when we refer to the “prospectus,” we are referring to both parts combined. This prospectus supplement and any free writing prospectus we authorizefor use in connection with this offering may add to, update or change information in the accompanying prospectus and the documents incorporated byreference into this prospectus supplement or the accompanying prospectus. If information in this prospectus supplement is inconsistent with the accompanying prospectus or with any document incorporated by referenceherein or therein that was filed with the SEC before the date of this prospectus supplement, you should rely on the information contained in thisprospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date,the statement in the document having the later date modifies or supersedes the earlier statement. This prospectus supplement, the accompanyingprospectus, the documents incorporated by reference into each and any free writing prospectus we authorize for use in connection with this offeringinclude important information about us, the securities and other information you should consider when making your investment decision. See“Information Incorporated by Reference” and “Where You Can Find Additional Information” in this prospectus supplement. We further note that the representations,